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SLPI (secretory leukocyte protease inhibitor) is a 107-residue non-glycosylated
protease inhibitor, which inhibits a wide range of serine proteases, trypsin,
chymotrypsin, neutrophil elastase, chymase and cathepsin G. X-ray crystal-
lographic analyses have shown that SLPI comprises two separate domains of
similar architecture [Gru ¨tter, Fendrich, Huber & Bode (1988), EMBO J. 7, 345–
351] and the C-terminal domain interacts with bovine  -chymotrypsin. In order
to understand SLPI’s multiple functions against various serine proteases, the
complex HNE (human neutrophil elastase) has been co-crystallized with
1/2SLPI (recombinant C-terminal domain of SLPI; Arg58–Ala107), which has a
biological activity similar to full SLPI. The 1/2SLPI and HNE complex structure
was solved at 1.7 A ˚ resolution, and compared with the interaction mechanism of
elaﬁn, which is a speciﬁc inhibitor of elastase. It was found that P1 Leu72i and six
hydrogen bonds between the main chains in the primary contact region have
sufﬁcient ability to inhibit HNE and PPE (porcine pancreatic elastase), and P5
Tyr68i is important in increasing the selectivity of 1/2SLPI against HNE. The
mechanisms of the functions of SLPI are relatively unknown, but the current
study could help understand the selectivity of SLPI against HNE and PPE.
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1. Introduction
The SLPI (secretory leukocyte protease inhibitor) similar domain
motif is present in several other secreted proteins called the WAP
four-disulﬁde core (WFDC) domain family. Elaﬁn is one of these
proteins (Wiedow et al., 1990, 1991; Zani et al., 2004), a 57-residue
protease inhibitor that is a potent and speciﬁc strong inhibitor of PPE
and HLE (human leukocyte elastase). However, the SLPI C-terminal
domain inhibits HNE but inhibits PPE weakly (Masuda et al., 1994).
The X-ray structure shows that elaﬁn inhibits PPE in a similar way
as the SLPI C-terminal domain (Tsunemi et al., 1996). How are these
differences in selectivity against serine proteases between SLPI and
elaﬁn caused? Elaﬁn and SLPI have multiple important roles both in
normal homeostasis and at the site of inﬂammation. These include
anti-protease and anti-microbial activity as well as modulation of the
response to LPS stimulation. Both are members of larger families of
proteins secreted predominantly at mucosal sites and are modulated
under multiple pathological conditions, and control the conditioning
of the innate immune system. The functions of SLPIs are still unclear
(Williams et al., 2006). We report here the details of their interactions
with 1/2SLPI and HNE and describe the comparison with elaﬁn:PPE
complexes (Tsunemi et al., 1996).
2. Materials and methods
2.1. Crystallization
1/2SLPI was designed as a half-size SLPI, which corresponds to the
C-terminal domain and is expressed in E. coli. HNE was purchased
from Elastin Products Company (Paciﬁc, MO, USA). To obtain the
HNE and 1/2SLPI complex, the mixed sample was dialyzed against
20 mM Na-acetate buffer (pH 5.0) using Slide-A-Lyzer (5000 Mw)
to remove excess 1/2SLPI molecules. The crystallization was
performed using the sitting-drop vapor-diffusion method at 293 K.
Jena Bioscience Screening kits were used for the initial condition
search. The crystals appeared from 2.0 M Na-formate at pH 4.5 in a
few days and grew to a typical crystal size of 0.4   0.2   0.01 mm
in one week.
2.2. Data collection and processing
Data collection was carried out under nitrogen stream at 100 K
using Quantum315 at beamline BL41XU of SPring-8. Paraton was
chosen as a cryoprotectant and added to the crystallization condition
40%(v/v). The crystal belongs to P42212 with unit-cell constants of a =
b = 106.64 A ˚ , c = 55.12 A ˚ . The data set was processed using Crystal
Clear 1.3.5. The initial phase was determined by molecular replace-
ment with only HNE using MOLREP (CCP4.6.01 suite).
2.3. Refinements
Reﬁnements were carried out using REFMAC5 (CCP4.6.01 suite).
After several cycles of map ﬁtting of the HNE protein structure,
we identiﬁed the electron density corresponding to 1/2SLPI. The
1/2SLPI model was constructed using QUANTA2000 (MSI) with
reference to the elaﬁn (Tsunemi et al., 1996) main-chain trace. The
crystallographic data are shown in Table 1.3. Results and discussions
3.1. Crystal structure of HNE and 1/2SLPI complex
Fig. 1(a) shows the complex structure of HNE and 1/2SLPI. In
the contact region there are no covalent bonds between HNE and
1/2SLPI. The main-chain trace of HNE shows no differences from
PDB (Protein Data Bank) id 1B0F (Cregge et al., 1998). 1/2SLPI
consists of four anti-parallel strands (strand from A to D) and four
disulﬁde bridges (Cys64i–Cys93i, Cys71i–Cys97i, Cys80i–Cys92i,
Cys86i–Cys101i), which keep the shape of 1/2SLPI like a rigid wedge.
There are a small number of intra-hydrogen bonds and electrostatic
interactions in the 1/2SLPI structure (Fig. 1b).
In these four strands, only two internal strands form a double-
stranded twisted  -sheet (Lys91i–Gly95i and Gly98i–Val102i)
connected by ﬁve main-chain–main-chain hydrogen bonds. These two
strands are joined by a  -hairpin loop at Met96i–Cys97i. No main-
chain–main-chain hydrogen bond is formed between the two parallel
strands A and C, and one hydrogen bond is formed between strands
B and D. In the region between the long loop AB and the adjacent
hairpin loop CD, only one hydrogen bond is formed, connecting N of
Cys71i and O of Met96i.
1/2SLPI has almost the same structure as the C-terminal domain of
the full SLPI structure (W. Bode, private communication), with the
root-mean-square deviation (RMSD) of the backbone atoms being
1.04 A ˚ for residues Arg58i–Ala107i. The AB loop (between strands
A and B) of 1/2SLPI binding to the active site of HNE has no serious
affect on the enzyme structure. Both 1/2SLPI and elaﬁn have four
disulﬁde bridges at the same positions. The sequence identity is 42%;
however, the P1-residue of elaﬁn is Ala24i. The main-chain structures
of the AB loop of both 1/2SLPI and elaﬁn are similar. The AB loop
of elaﬁn should have a large ﬂexibility, like 1/2SLPI (unpublished
NMR data).
The primary interaction appears to be the P1-residue Leu72i,
located in the S1 pocket, and the carbonyl oxygen accommodated in
the oxyanion hole. 1/2SLPI:HNE has almost similar hydrogen bonds
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Table 1
Crystallographic data and reﬁnement statistics of the HNE with 1/2SLPI complex.
Values in parentheses are for the outer shell (1.74–1.70 A ˚ ).
Data collection
Space group P42212
Cell dimensions (A ˚ ) a = b = 106.64, c = 55.12
Resolution (A ˚ ) 38.32–1.70 (1.74–1.70)
Total observations 419005
No. of unique reﬂections 35374
Redundancy 11.84 (11.96)
Completeness (%) 99.5 (99.6)
I/ (I) 18.5 (7.9)
Rmerge (%) 6.4 (27.2)
Ramachandran plot
Core angles (%) 89.6
Additional allowed angles (%) 9.5
Generous allowed angles (%) 0.9
Disallowed angles (%) 0
Reﬁnement statistics
Completeness for range (%) 99.45
Reﬂections used for reﬁnement 33575
Reﬂections used for Rfree calculations 1770 (5%)
Crystallographic R (%) 20.3
Rfree (%) 23.1
No. of protein atoms/average B-factor (A ˚ 2) 1636/18.7
No. of inhibitor atoms/average B-factor (A ˚ 2) 374/24.5
No. of sugar atoms/average B-factor (A ˚ 2) 48/25.9
RMS deviations from ideal geometry
Bond distances (A ˚ ) 0.011
Bond angles ( ) 1.268
Table 2
Inhibition constant (Ki values) of elaﬁn (Zani et al., 2004) and 50% inhibitory
concentrations (IC50) of 1/2SLPI and against some serine proteases (Masuda et al.,
1994).
Ki (M) of elaﬁn IC50 of 1/2SLPI
57 amino acids A1–G57 49 amino acids R58–A107
42% identity with 1/2SLPI C-terminal domain of SLPI
H. neutrophil elastase 1   10
 10 1.3   10
 8
P. pancreatic elastase 1   10
 9 3.3   10
 5
H. cathepsin G – 8.0   10
 9
B. pancreatic chymotrypsin – 8.0   10
 9
B. pancreas trypsin – 2.0   10
 6
Figure 1
(a) The structure of the HNE and 1/2SLPI complex. The C  linkage of 1/2SLPI is shown in blue and the C  linkage of HNE is in yellow. (b) Schematic representation of the
polypeptide chain folding of 1/2SLPI with its disulﬁde connectivities. Disulﬁde bonds are indicated by thin lines. The blue arrows show the twisted  -sheet (strands C, D), and
the blue rectangles show the strands (strand A, B). AB and CD loops are shown by pink lines. Intramolecular hydrogen bonds are indicated by dashed lines, with distances
shown. Intramolecular van der Waals interactions are also indicated at the bottom of the ﬁgure.at P20–P3 in the primary contact site as elaﬁn:PPE. Another hydrogen
bond, Tyr68i(OH)   Arg217A(N"1), in the primary contact region is
added (Fig. 2a). Met96i (CD loop) is located near Phe215 with a
longer distance than the usual van der Waals contact in the secondary
contact region.
On the other hand, elaﬁn has additional hydrogen bonds between
the carbonyl oxygen of Leu20i (P5) and the main-chain NH of
Arg217A in the primary contact region, and between the hydroxyl
group of Ser48i and the carbonyl oxygen of Asp97 shown in Fig. 2(b)
(Tsunemi et al., 1996). The RMSD of the backbone atoms between
1/2SLPI and elaﬁn is 1.01 A ˚ , calculated by superposing residues
Arg59i–Val105i of 1/2SLPI onto Thr11i–Gln57i of elaﬁn. As shown in
Table 2, 1/2SLPI shows a wide range of inhibitory activity against
some serine proteases. On the other hand, elaﬁn is a potent and
speciﬁc protein inhibitor of PPE and HNE.
3.2. Difference in the inhibitory mechanism for elastases between
elafin and 1/2SLPI
1/2SLPI:HNE has a similar interaction mode at P20–P3 in the
primary contact region as elaﬁn:PPE. Figs. 3(a) and 3(b) show the S1
pocket of 1/2SLPI:HNE and elaﬁn:PPE, respectively. They show that
elaﬁn does not ﬁll the S1 pocket in the elaﬁn:PPE complex structure
and that SLPI ﬁlls the S1 pocket of HNE better. Leu72i (P1)
of 1/2SLPI provides a large contribution in the recognition with
HNE and PPE (Eisenberg et al., 1990).
Fig. 3(c) shows PPE superposing onto
1/2SLPI:HNE; the S1 pocket of PPE is
similar to those of HNE. 1/2SLPI should
show the same inhibitory activity against
PPE on the S1 pocket, but 1/2SLPI inhibits
HNE more than PPE (Table 2).
To understand 1/2SLPI’s selectivity for
HNE, we compared the interface of HNE
and PPE around P5 and found a remark-
able difference in these structures (Fig. 3).
In the PPE’s binding interfaces, Tyr68i (P5)
conﬂicts with a region (Ser169–Val176) of
PPE (shown in Figs. 3d and 3e). Tyr68i
may be ﬂipping away to avoid the conﬂict
and cannot interact with PPE. In the
1/2SLPI:HNE complex, 1/2SLPI requires at
least six hydrogen bonds between the main
chains at P20–P3 for the inhibitory activity
owing to Leu72i (P1) occupation in the S1
pocket. Then the additional interactions at
Tyr68i (P5) are used to increase the inhi-
bitory activity of 1/2SLPI against HNE, but
the interaction of the second contact region
is not so critical.
On the other hand, elaﬁn needs a full set
of hydrogen-bonding interactions (seven
hydrogen bonds of the main chain in the
primary contact region and one in the
secondary contact region) which should be
essential for the inhibitory activity because
Ala24i (P1) is insufﬁcient in occupying the
S1 site. The interacting mode of elaﬁn:PPE
may be kept in the elaﬁn:HNE complex
structure. It seems that the P1 and P5 resi-
dues of 1/2SLPI are important residues
causing the selectivity against HNE.
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Figure 2
Schematic representation of the hydrogen-bonding interactions between the
contact regions of (a) HNE and 1/2SLPI and (b) PPE and elaﬁn (Tsunemi et al.,
1996). Inhibitor residues are designated by ‘i’ after the sequence number.
Intermolecular hydrogen bonds are indicated by dashed lines.
Figure 3
Electrostatic surface representations of (a) the HNE complex with 1/2SLPI (ball and stick model), and (b) the
PPE:elaﬁn complex around the S1 pocket. Superposed representations of the PPE molecule onto HNE of the
X-ray structure HNE:1/2SLPI. The solid surface shows HNE and the meshed surface shows PPE. Comparison of
HNE and PPE (purple mesh) around (c) the S1 pocket and (d) the S5 pocket. (e) The sequence alignment
between HNE and PPE around the S5 pocket. The conﬂict residues of PPE with Y68i are shown in the purple
square.4. Conclusion
The current study shows the interaction mode between 1/2SLPI and
HNE and it is similar to the elaﬁn:PPE interaction modes. Although
elaﬁn inhibits both HNE and PPE equally, 1/2SLPI prefers HNE to
PPE. We found that there were two important structural mechanisms
which explained the selectivity of 1/2SLPI. First, the sufﬁcient inhi-
bitory activity of 1/2SLPI consists of six hydrogen bonds between the
main chains at P20–P3, owing to P1 (Leu72i) occupation of the S1
pocket. Second, additional interaction at P5 (Tyr68i) is possible in
HNE, but impossible in PPE. P1 and P5 are critical residues for the
selectivity of 1/2SLPI against HNE.
These recognition mechanisms for HNE may provide important
information for understanding the multiple function of 1/2SLPI. To
understand the versatility of 1/2SLPI against other serine proteases
(chymotrypsin, trypsin, cathepsin etc.), we need additional structural
information involving the structure determination of some other
serine protease complexes with 1/2SLPI.
The crystal structure coordinates have been deposited with the
Protein Data Bank (code 2Z7F).
We thank Dr Wolfram Bode (Max-Planck -Institute fu ¨r Biochimie)
for the coordinates of full SLPI.
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